Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hochhaus, A.
1521  Ergebnisse:
Personensuche X
?
1

Structural, chemical, and magnetic investigation of a graph..:

Weinert, P ; Hochhaus, J ; Kesper, L...
Nanotechnology.  35 (2024)  16 - p. 165702 , 2024
Link: https://doi.org/10.1088/..
 
?
2

CO169 Pan-Stakeholder Core Outcome Set (COS) Definition for..:

Lang, K. ; Bereczky, T. ; Geissler, J....
Value in Health.  26 (2023)  12 - p. S44 , 2023
Link: https://doi.org/10.1016/..
 
?
3

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 ..:

Hammersen, J. ; Birndt, S. ; Döhner, K....
Leukemia.  37 (2023)  9 - p. 1879-1886 , 2023
Link: https://doi.org/10.1038/..
 
?
4

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB V..:

Hughes, T. ; Cortes, J. ; Takahashi, N....
HemaSphere.  6 (2022)  - p. 1783-1784 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIEN..:

Gambacorti-Passerini, C. ; Brümmendorf, T. H. ; Ernst, T....
HemaSphere.  6 (2022)  - p. 614-615 , 2022
Link: https://doi.org/10.1097/..
 
?
6

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 S..:

Rea, D. ; Hochhaus, A. ; Mauro, M. J....
HemaSphere.  6 (2022)  - p. 56-57 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS W..:

Apperley, J. ; Kantarjian, H. ; Deininger, M....
HemaSphere.  6 (2022)  - p. 602-603 , 2022
Link: https://doi.org/10.1097/..
 
?
8

MSR19 A Matching-Adjusted Indirect Comparison of Asciminib ..:

Atallah, EL ; Maheshwari, V ; Mauro, MJ...
Value in Health.  25 (2022)  7 - p. S521 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Molekulare Onkologie:

Hochhaus, A. ; Krause, M. ; Schmidberger, H.
Der Onkologe.  28 (2022)  2 - p. 92-94 , 2022
Link: https://doi.org/10.1007/..
 
?
10

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIA..:

Stegelmann, F. ; Jahn, E. ; Koschmieder, S....
HemaSphere.  6 (2022)  - p. 945-946 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PAT..:

Hughes, T. ; Cortes, J. E. ; Réa, D....
HemaSphere.  6 (2022)  - p. 599-600 , 2022
Link: https://doi.org/10.1097/..
 
?
12

PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OP..:

Breccia, M. ; Turkina, A. ; Boquimpani, C....
HemaSphere.  6 (2022)  - p. 1781-1782 , 2022
Link: https://doi.org/10.1097/..
 
?
13

The impact of specific cytokine directed treatment on sever..:

Reuken, P. A. ; Rüthrich, M. M. ; Hochhaus, A....
Leukemia.  35 (2021)  12 - p. 3613-3615 , 2021
Link: https://doi.org/10.1038/..
 
?
14

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with..:

La Rosée, F. ; Bremer, H. C. ; Gehrke, I....
Leukemia.  34 (2020)  7 - p. 1805-1815 , 2020
Link: https://doi.org/10.1038/..
 
?
15

Holding CoVID in check through JAK? The MPN-approved compou..:

Heidel, F. ; Hochhaus, A.
Leukemia.  34 (2020)  7 - p. 1723-1725 , 2020
Link: https://doi.org/10.1038/..
 
1-15